SCHEMBL3016908

SCHEMBL3016908

Cc1cccc(C)c1Cc1csc(N2CCC(S(=O)(=O)c3ccccc3Cl)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSS P25774 6/20 0.44
DCTPP1 Q9H773 1/20 0.36
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
RAB9A P51151 3/20 0.35
HSD11B1 P28845 2/20 0.34
HSD17B1 P14061 1/20 0.34
HSD17B2 P37059 1/20 0.34
NPC1 O15118 2/20 0.34
DNM1L O00429 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
FAAH O00519 1/20 0.33
EPHX2 P34913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014628 0.93 CTSS (0.43) CTSSDCTPP1MEN1LMNAKMT2A
SCHEMBL3015218 0.93 CTSS (0.41) CTSSDCTPP1MEN1LMNAKMT2A
SCHEMBL3010356 0.90 CTSS (0.42) CTSSDCTPP1MEN1LMNAKMT2A
SCHEMBL3019338 0.90 CTSS (0.38) CTSSSMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL3011124 0.90 SMN1; SMN2 (0.37) CTSSMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL3022015 0.90 CTSS (0.42) CTSSDCTPP1MEN1LMNAKMT2A
SCHEMBL3022762 0.89 LMNA (0.36) CTSSMEN1LMNAKMT2AMAPK1
SCHEMBL3016336 0.89 CTSS (0.41) CTSSDCTPP1MEN1LMNAKMT2A
SCHEMBL3012400 0.88 CTSS (0.48) CTSSMEN1LMNAKMT2AMAPK1
SCHEMBL3014981 0.88 CTSS (0.37) CTSSMEN1KMT2ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885DCTPP1 1883/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.